Clinical Trials Directory

Trials / Terminated

TerminatedNCT05127681

Bone Microarchitecture in Men With Hemophilia

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
Male
Age
20 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Hemophilia A and B are hereditary sex-linked deficiencies of coagulation factors VIII and IX characterized by bleeding. Their modern therapy increases life expectancy and risk of age-related diseases, e.g., osteoporosis. Hemophilia-specific risk factors impair formation of peak bone mass and accelerate bone loss. Fractures are more frequent in hemophilic men vs. age-matched men and induce bleeding which is aggravated by manipulations and surgical intervention. The hypothesis of this study is that hemophilic men have poor bone microarchitecture (assessed by High-resolution peripheral quantitative computed tomography (HR-pQCT)) related to an imbalance between bone formation and resorption (assessed by bone turnover markers (BTM) and bone biomarkers). The study aims to assess the difference in low trabecular number (Tb.N) at the distal radius between hemophilic men (cases) and age- height-weight-ethnicity and smoking-matched healthy men (controls). Correlation between BTM and Tb.N will be also studied. Biologic markers of bone remodeling (C-terminal telopeptide of type I collagen (PINP), N-terminal propeptide of type I procollagen (CTX-I), periostin) will be studied.

Conditions

Interventions

TypeNameDescription
RADIATIONHR-pQCTPatients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
BIOLOGICALBlood samplePatients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
RADIATIONDual energy X-ray absorptiometryA dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
OTHERmedical data collectionData of healthy men is already available

Timeline

Start date
2023-08-01
Primary completion
2024-02-06
Completion
2024-02-06
First posted
2021-11-19
Last updated
2024-04-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05127681. Inclusion in this directory is not an endorsement.